RU2711114C2 - Т-клетки, перенацеленные в отношении cd123-специфичного химерного антигенного рецептора, и способы их применения - Google Patents

Т-клетки, перенацеленные в отношении cd123-специфичного химерного антигенного рецептора, и способы их применения Download PDF

Info

Publication number
RU2711114C2
RU2711114C2 RU2015140624A RU2015140624A RU2711114C2 RU 2711114 C2 RU2711114 C2 RU 2711114C2 RU 2015140624 A RU2015140624 A RU 2015140624A RU 2015140624 A RU2015140624 A RU 2015140624A RU 2711114 C2 RU2711114 C2 RU 2711114C2
Authority
RU
Russia
Prior art keywords
cells
seq
aml
nucleic acid
acid molecule
Prior art date
Application number
RU2015140624A
Other languages
English (en)
Russian (ru)
Other versions
RU2015140624A (ru
Inventor
Стивен ФОРМЭН
Армен МАРДАЙРОС
Original Assignee
Сити Оф Хоуп
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2711114(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сити Оф Хоуп filed Critical Сити Оф Хоуп
Publication of RU2015140624A publication Critical patent/RU2015140624A/ru
Application granted granted Critical
Publication of RU2711114C2 publication Critical patent/RU2711114C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
RU2015140624A 2013-03-15 2014-03-14 Т-клетки, перенацеленные в отношении cd123-специфичного химерного антигенного рецептора, и способы их применения RU2711114C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/844,048 2013-03-15
US13/844,048 US9657105B2 (en) 2013-03-15 2013-03-15 CD123-specific chimeric antigen receptor redirected T cells and methods of their use
PCT/US2014/029109 WO2014144622A2 (en) 2013-03-15 2014-03-14 Cd123-specific chimeric antigen receptor redirected t cells and methods of their use

Publications (2)

Publication Number Publication Date
RU2015140624A RU2015140624A (ru) 2017-04-26
RU2711114C2 true RU2711114C2 (ru) 2020-01-15

Family

ID=51527938

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015140624A RU2711114C2 (ru) 2013-03-15 2014-03-14 Т-клетки, перенацеленные в отношении cd123-специфичного химерного антигенного рецептора, и способы их применения

Country Status (14)

Country Link
US (3) US9657105B2 (https=)
EP (2) EP3626247B1 (https=)
JP (4) JP6588004B2 (https=)
KR (4) KR102297918B1 (https=)
CN (2) CN105392887B (https=)
AU (3) AU2014228911A1 (https=)
BR (1) BR112015023701B1 (https=)
CA (1) CA2907216C (https=)
DK (1) DK2968415T3 (https=)
ES (1) ES2747099T3 (https=)
IL (4) IL289883B2 (https=)
MX (2) MX2015013195A (https=)
RU (1) RU2711114C2 (https=)
WO (1) WO2014144622A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2779315C2 (ru) * 2017-02-17 2022-09-06 Рубиус Терапьютикс, Инк. Функционализированные эритроидные клетки

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
WO2015010096A1 (en) 2013-07-18 2015-01-22 Baylor College Of Medicine Method of enhancing potency of immune cells
CN113307880B (zh) * 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
KR102375998B1 (ko) * 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
PL3119807T3 (pl) 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
EP4205749A1 (en) * 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
BR112017005631A2 (pt) * 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
US20170333480A1 (en) * 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3865139B1 (en) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
RS61907B1 (sr) * 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
US10738118B2 (en) 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
DK3909972T5 (da) 2015-06-19 2024-08-05 Sebastian Kobold Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
CN107709356A (zh) 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
CA2992989A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
JP6751493B2 (ja) * 2015-08-05 2020-09-09 セルレブメド インコーポレーテッド キメラ抗原受容体及びキメラ抗原受容体が発現されたｔ細胞
EP3569244A1 (en) * 2015-09-23 2019-11-20 CytoImmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
EP3359574B1 (en) 2015-10-06 2020-04-22 City of Hope Chimeric antigen receptors targeted to psca
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
JP7018387B2 (ja) 2015-10-16 2022-02-10 ルードヴィッヒ－マクシミリアン－ユニヴェルシタート ミュンヘン 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
KR20180083874A (ko) * 2015-11-04 2018-07-23 사울 제이. 프라이스맨 Her2를 표적화하는 키메라 항원 수용체
EP4212547A1 (en) * 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
CN109715808A (zh) 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
AU2017291262A1 (en) 2016-06-30 2019-01-03 F. Hoffmann-La Roche Ag Improved adoptive T-cell therapy
BR112019002035A2 (pt) 2016-08-01 2019-05-14 Novartis Ag tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
BR112019010061A2 (pt) * 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
RU2019134273A (ru) * 2017-03-31 2021-04-30 Займворкс Инк. Конструкты индуктора презентации антигена опухоли и их использование
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
AU2018295994B2 (en) * 2017-07-07 2025-02-06 Hanmi Pharm. Co., Ltd. Novel therapeutic enzyme fusion protein and use thereof
KR20260026092A (ko) 2017-09-19 2026-02-25 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
RU2020116579A (ru) * 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2019094360A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20250070609A (ko) 2017-11-14 2025-05-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
RS67119B1 (sr) 2017-11-14 2025-09-30 Arcellx Inc Polipeptidi koji obuhvataju d domen i njihove upotrebe
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CN108276495B (zh) * 2018-01-24 2022-03-18 博生吉医药科技(苏州)有限公司 靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
EA202092044A1 (ru) 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения
US20190328781A1 (en) * 2018-04-06 2019-10-31 Mustang Bio, Inc. Manufacturing methods for cell-based therapeutic compositions
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
WO2020007593A1 (en) * 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3105816A1 (en) * 2018-07-10 2020-01-16 Precigen, Inc. Ror-1 specific chimeric antigen receptors and uses thereof
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020113054A1 (en) * 2018-11-30 2020-06-04 Mustang Bio, Inc. Methods of treatment using decitabine and a cd123-targeted therapy
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113874391B (zh) 2019-02-20 2025-10-28 希望之城公司 靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220143087A1 (en) 2019-03-08 2022-05-12 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
US20220145252A1 (en) 2019-03-29 2022-05-12 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CN110904048A (zh) * 2019-12-04 2020-03-24 合肥中科干细胞再生医学有限公司 一种car-cd123t2嵌合抗原受体t细胞及其应用
CA3161103A1 (en) * 2019-12-16 2021-06-24 Carl Deselm Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体
JP2023517063A (ja) 2020-03-10 2023-04-21 マサチューセッツ インスティテュート オブ テクノロジー 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物
BR112022017924A2 (pt) 2020-03-10 2022-12-20 Massachusetts Inst Technology Composições e métodos para imunoterapia de câncer npm1c-positivo
CN113493772B (zh) * 2020-04-08 2022-10-18 华中农业大学 可分泌性表达免疫毒素的嵌合抗原受体修饰的免疫细胞
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CN112079927B (zh) * 2020-09-18 2021-12-28 西安桑尼赛尔生物医药有限公司 一种cd123结合蛋白、含其的car及其应用
CN112521505B (zh) * 2020-12-11 2022-07-29 华道(上海)生物医药有限公司 抗cd123抗体及其应用
CN112646033B (zh) * 2020-12-16 2022-04-12 北京艺妙神州医药科技有限公司 靶向cd123的嵌合抗原受体及其用途
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20250295693A1 (en) 2021-08-18 2025-09-25 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
AU2023205629A1 (en) 2022-01-05 2024-08-15 Fundació De Recerca Clinic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer Anti-cd84 antibodies and chimeric antigen receptors
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024094004A1 (zh) * 2022-11-03 2024-05-10 重庆精准生物技术有限公司 靶向cd123的全人源抗体及其应用
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024123836A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Immune-activating complexes
WO2024123835A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
CN117430721B (zh) * 2023-10-25 2024-06-25 北京景达生物科技有限公司 Cd123靶向car-nk细胞的制备及其应用
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025255266A1 (en) 2024-06-05 2025-12-11 Dynamic Cell Therapies, Inc. Engineered polypeptides for immune cell activation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009873B1 (ru) * 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130004514A1 (en) * 2011-06-06 2013-01-03 Novo Nordisk A/S Therapeutic antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN113307880B (zh) 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
BR112017005631A2 (pt) 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009873B1 (ru) * 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130004514A1 (en) * 2011-06-06 2013-01-03 Novo Nordisk A/S Therapeutic antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
US 2013004514 А1 *
РОЙТ А. и др., Иммунология, пер. с анг. - М.: Мир, 2000, стр.10-13. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2779315C2 (ru) * 2017-02-17 2022-09-06 Рубиус Терапьютикс, Инк. Функционализированные эритроидные клетки

Also Published As

Publication number Publication date
JP2016514457A (ja) 2016-05-23
US9657105B2 (en) 2017-05-23
EP2968415B1 (en) 2019-07-31
CA2907216C (en) 2024-02-27
JP2020010699A (ja) 2020-01-23
BR112015023701B1 (pt) 2022-01-11
JP2022191388A (ja) 2022-12-27
CN111926028A (zh) 2020-11-13
EP3626247B1 (en) 2023-07-12
EP2968415A2 (en) 2016-01-20
WO2014144622A2 (en) 2014-09-18
US11918606B2 (en) 2024-03-05
KR102556831B1 (ko) 2023-07-19
JP6793800B2 (ja) 2020-12-02
WO2014144622A3 (en) 2015-06-11
DK2968415T3 (da) 2019-10-21
EP3626247A1 (en) 2020-03-25
BR112015023701A2 (pt) 2017-07-18
EP2968415A4 (en) 2017-01-04
KR102297918B1 (ko) 2021-09-03
CN105392887A (zh) 2016-03-09
US20200254023A1 (en) 2020-08-13
NZ712351A (en) 2021-07-30
IL289883B (en) 2022-12-01
US20170260277A1 (en) 2017-09-14
HK1222677A1 (zh) 2017-07-07
IL281562A (en) 2021-05-31
IL241668B (en) 2021-04-29
IL298332A (en) 2023-01-01
IL289883A (en) 2022-03-01
AU2021202705A1 (en) 2021-05-27
KR102416258B1 (ko) 2022-07-05
AU2019202394A1 (en) 2019-05-02
MX2020001358A (es) 2020-08-20
KR20160012991A (ko) 2016-02-03
KR102506668B1 (ko) 2023-03-07
RU2015140624A (ru) 2017-04-26
KR20210111879A (ko) 2021-09-13
JP7160882B2 (ja) 2022-10-25
AU2014228911A1 (en) 2015-10-08
BR112015023701A8 (pt) 2020-03-10
IL281562B (en) 2022-02-01
MX2015013195A (es) 2016-04-15
US10660916B2 (en) 2020-05-26
US20140271582A1 (en) 2014-09-18
JP6588004B2 (ja) 2019-10-09
IL289883B2 (en) 2023-04-01
CN105392887B (zh) 2020-05-29
KR20230035704A (ko) 2023-03-14
KR20220098048A (ko) 2022-07-08
CA2907216A1 (en) 2014-09-18
JP2021036886A (ja) 2021-03-11
ES2747099T3 (es) 2020-03-10

Similar Documents

Publication Publication Date Title
US11918606B2 (en) CD123-specific chimeric antigen receptor redirected t cells and methods of their use
CN107074957B (zh) 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
JP2023087005A (ja) Ｓｔｒｅｐ－タグ特異的結合タンパク質およびその使用
HK40026837A (en) Cd123-specific chimeric antigen receptor redirected t cells and methods of their use
HK1222677B (zh) Cd123特异性嵌合抗原受体重导向性t细胞及其使用方法
KR20230013258A (ko) T 세포 재유도 치료제 및 vla-4 부착 경로 억제제를 포함하는 조성물